0001193125-21-214667.txt : 20210714 0001193125-21-214667.hdr.sgml : 20210714 20210714081130 ACCESSION NUMBER: 0001193125-21-214667 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210714 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210714 DATE AS OF CHANGE: 20210714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 211089300 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 8-K 1 d173270d8k.htm 8-K 8-K
false 0001668243 0001668243 2021-07-14 2021-07-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2021

 

 

UROGEN PHARMA LTD.

(Exact name of registrant as specified in its charter)

 

 

 

Israel   001-38079   98-1460746

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

400 Alexander Park Drive, 4th Floor

Princeton, New Jersey

  08540
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: +1 (646) 768-9780

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Ordinary Shares, par value NIS0.01 per share   URGN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On July 14, 2021, UroGen Pharma Ltd. (the “Company”) issued a press release announcing certain preliminary financial results as of and for the quarter ended June 30, 2021. A copy of this press release is attached to this report as Exhibit 99.1. The information in this Item 2.02 and the attached exhibit are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 8.01

Other Events.

Although our financial results as of and for the second quarter ended June 30, 2021 are not yet finalized, based on currently available information, we expect net product revenue from Jelmyto® sales for the second quarter ended June 30, 2021 to be approximately $13.0 million, representing an increase of over 70% compared to the first quarter of 2021 and the highest quarterly sales since Jelmyto was launched in June 2020. Additionally, operating expenses in the second quarter of 2021 are anticipated to be in the range of $33 – $38 million. Cash, cash equivalents and marketable securities as of June 30, 2021 are expected to be approximately $129.0 million.

The preliminary financial results set forth above are based on management’s initial review of the Company’s results as of and for the quarter ended June 30, 2021 and are subject to revision based upon the Company’s quarter-end closing procedures and the completion of the review by the Company’s external auditors of the Company’s quarter-end financial statements. Actual results may differ materially from these preliminary results as a result of the completion of quarter-end closing procedures, final adjustments, and other developments arising between now and the time that the Company’s financial results are finalized. In addition, these preliminary results are not a comprehensive statement of the Company’s financial results for the quarter ended June 30, 2021, should not be viewed as a substitute for complete financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the Company’s results for any future period.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.   

Description

99.1    Press Release dated July 14, 2021
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 14, 2021     UROGEN PHARMA LTD.
    By:  

/s/ Molly Henderson

      Molly Henderson
      Chief Financial Officer
EX-99.1 2 d173270dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

 

   

73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 2021

 

   

2Q 2021 operating expenses anticipated in the range of $33 to $38 million

 

   

Full 2Q 2021 financial results and conference call to be reported on Wednesday, August 4, 2021

PRINCETON, N.J. - July 14, 2021— UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it expects net product revenue from Jelmyto sales for the second quarter ended June 30, 2021, to be approximately $13.0 million, representing an increase of over 70% compared to the first quarter of 2021 and the highest quarterly sales since Jelmyto was launched in June 2020. Additionally, operating expenses in the second quarter of 2021 are anticipated to be in the range of $33 to $38 million. Cash, cash equivalents and marketable securities as of June 30, 2021, are expected to be approximately $129.0 million.

“Our strong, preliminary top line results for the second quarter of 2021 have validated our belief that increased vaccination rates and the general re-opening of activities throughout the United States would correlate to increased adoption of Jelmyto as an innovative treatment for patients with low-grade upper tract urothelial cancer,” said Liz Barrett, President and Chief Executive Officer of UroGen. “The momentum in Jelmyto sales gives us increased confidence in physician adoption of this paradigm shifting therapy. We are optimistic that this trend will continue as our commercial team actively engages in-person with healthcare providers to activate new sites and increase usage at existing sites. We look forward to reporting our full results for the second quarter of 2021 in early August.”

The Company expects to report full financial results for the second quarter ended June 30, 2021, and host a conference call on Wednesday, August 4, 2021. A press release with the details for the conference call will be issued approximately one week prior to the planned reporting date.

Preliminary Financial Results

The preliminary financial results set forth above are based on management’s initial review of the Company’s results as of and for the quarter ended June 30, 2021, and are subject to revision based upon the Company’s quarter-end closing procedures and the completion of the review by the Company’s external auditors of the Company’s quarter-end financial statements. Actual results may differ materially from these preliminary results as a result of the completion of quarter-end closing procedures, final adjustments, and other developments arising between now and the time that the Company’s financial results are finalized. In addition, these preliminary results are not a comprehensive statement of the Company’s financial results for the quarter ended June 30, 2021, should not be viewed as a substitute for complete financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the Company’s results for any future period.

2021 Operating Expense Guidance

The Company affirms its previously announced guidance for full-year operating expenses in the range of $155 to $165 million, including non-cash share-based compensation expense of $24 to $28 million, subject to market conditions.


About Jelmyto®

Jelmyto (mitomycin) for pyelocalyceal solution, is a drug formulation of mitomycin indicated for the treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC). Utilizing the RTGel technology platform, UroGen’s proprietary sustained release, hydrogel-based formulation, Jelmyto is designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. Jelmyto is delivered to patients using standard ureteral catheters or nephrostomy tube. The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC. On April 15, 2020, the FDA approved Jelmyto, making it the first drug approved for the treatment of LG-UTUC in adult patients.

APPROVED USE FOR JELMYTO

JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

IMPORTANT SAFETY INFORMATION

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:

 

 

are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.

Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose.

Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.

 

 

are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.

 

 

Tell your healthcare provider if you take water pills (diuretic).

How will I receive JELMYTO?

 

 

Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.

 

 

You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider’s instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.

 

 

JELMYTO is given to your kidney through a tube called a catheter.

 

 

During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.

After receiving JELMYTO:

 

 

JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.


 

To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.

 

 

Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.

JELMYTO may cause serious side effects, including:

 

 

Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.

 

 

Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.

The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda/gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

About Upper Tract Urothelial Cancer (UTUC)

Urothelial cancer is the ninth most common cancer globally and the eighth most lethal neoplasm in men in the U.S. Between five percent and ten percent of primary urothelial cancers originate in the ureter or renal pelvis and are collectively referred to as upper tract urothelial cancers (UTUC). In the U.S., there are approximately 6,000 - 7,000 new or recurrent low-grade UTUC patients annually. Most cases are diagnosed in patients over 70 years old, and these older patients often face comorbidities. There are limited treatment options for UTUC, with the most common being endoscopic surgery or nephroureterectomy (removal of the entire kidney and ureter). These treatments can lead to a high rate of recurrence and relapse.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.


Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: our expected revenue and other financial results as of and for the quarter ended June 30, 2021; our full-year 2021 operating expense guidance; our belief that physicians will continue to adopt Jelmyto and that the momentum in Jelmyto sales observed over the second quarter of 2021 will continue; our belief that Jelmyto will be a paradigm shifting therapy; and the potential of UroGen’s proprietary RTGel technology platform to improve therapeutic profiles of existing drugs. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the risk that our actual revenue or other financial results as of and for the quarter ended June 30, 2021 may differ materially from those set forth in this press release as a result of the completion of quarter-end closing procedures; the timing and success of clinical trials and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; Jelmyto may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success as a result of significant competition with competing technologies and other factors; complications associated with commercialization activities, including complications resulting from the ongoing COVID-19 pandemic; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and personnel; and any negative effects on UroGen’s business, commercialization and product development plans caused by or associated with COVID-19. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Form 10-Q filed with the SEC on May 13, 2021, and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

JELMYTO® and UroGen® are registered trademarks of UroGen Pharma, Ltd.

INVESTOR CONTACTS:

Sara Blum Sherman

Head of Investor Relations

investors@urogen.com

Lee Roth

lroth@burnsmc.com

212-213-0006

MEDIA CONTACT:

Eric Van Zanten

Head of Communications

Eric.VanZanten@urogen.com

610-529-6219

EX-101.SCH 3 urgn-20210714.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 urgn-20210714_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 urgn-20210714_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g173270g69o31.jpg GRAPHIC begin 644 g173270g69o31.jpg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end XML 7 d173270d8k_htm.xml IDEA: XBRL DOCUMENT 0001668243 2021-07-14 2021-07-14 false 0001668243 8-K 2021-07-14 UROGEN PHARMA LTD. L3 001-38079 98-1460746 400 Alexander Park Drive 4th Floor Princeton NJ 08540 +1 (646) 768-9780 false false false false Ordinary Shares, par value NIS0.01 per share URGN NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jul. 14, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001668243
Document Type 8-K
Document Period End Date Jul. 14, 2021
Entity Registrant Name UROGEN PHARMA LTD.
Entity Incorporation State Country Code L3
Entity File Number 001-38079
Entity Tax Identification Number 98-1460746
Entity Address, Address Line One 400 Alexander Park Drive
Entity Address, Address Line Two 4th Floor
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code +1 (646)
Local Phone Number 768-9780
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Ordinary Shares, par value NIS0.01 per share
Trading Symbol URGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d173270d8k.htm d173270dex991.htm urgn-20210714.xsd urgn-20210714_lab.xml urgn-20210714_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d173270d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d173270d8k.htm" ] }, "labelLink": { "local": [ "urgn-20210714_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "urgn-20210714_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "urgn-20210714.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "urgn", "nsuri": "http://www.urogen.com/20210714", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d173270d8k.htm", "contextRef": "duration_2021-07-14_to_2021-07-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d173270d8k.htm", "contextRef": "duration_2021-07-14_to_2021-07-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.urogen.com//20210714/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-21-214667-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-214667-xbrl.zip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end